Article Text

PDF
FRI0046 Anti-Carbamylated Protein Antibodies Precede the Onset of Symptoms of Rheumatoid Arthritis in A Swedish Biobank Cohort
  1. M. Brink1,
  2. M.K. Verheul2,
  3. J. Rönnelid3,
  4. R.E. Toes4,
  5. L. Klareskog5,
  6. L.L. Trouw4,
  7. S. Rantapää Dahlqvist1
  1. 1Public Health & Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden
  2. 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
  3. 3Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
  4. 4Rheumatology, Leiden University Medical Center, Leiden, Netherlands
  5. 5Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

Abstract

Background Antibodies against citrullinated peptides of several specificities (ACPAs) have been found to predate the onset of symptoms of rheumatoid arthritis (RA) by years. The presence of a new auto-antibody system, anti-carbamylated protein (anti-CarP) antibodies has been identified in rheumatoid arthritis (RA) even predating the disease onset. Anti-CarP antibodies were associated with RA irrespectively of ACPA status.

Objectives The presence of anti-CarP antibodies was evaluated in samples from individuals who subsequently developed RA before symptoms of joint disease and also after disease onset.

Methods 223 individuals, with 423 samples, who were identified before onset of symptoms of RA (median 5.2years IQR 2.6 – 8.9 years), as donors to the Medical Biobank of Northern Sweden. 192 of them were also sampled at the time of diagnose, and 197 population controls were identified from the Medical Biobank for analysis of anti-CarP IgG antibodies with ELISA as previously described (1). All samples were also analysed for anti-CCP2 antibodies with ELISA (Euro-Diagnostica). Cut-off levels were identified by receiver operating characteristic (ROC) curves with 97% specificity for anti-CarP.

Results The concentration of anti-CarP was significantly increased in the pre-symptomatic individuals compared with controls (median (IQR) 44.0 (142.6) AU/mL vs. 7.9 (43) AU/mL, p<0.001) and increased significantly after disease onset to 198.9 (379.1) AU/mL. The sensitivity for anti-CarP antibodies in the pre-symptomatic individuals including all samples was 13.9% (95%CI 11-17.6%,) as compared to 42.2% (95%CI 35.4-49.3,) after RA was diagnosed. The concentration of antibodies increased significantly the closer to disease onset the sample was collected. Sensitivity, less than 3 years before symptom onset, was 18.6% (95%CI 12.8-26.3). 5.1% of the anti-CCP negative pre-symptomatic individuals were anti-CarP ab positive and 10.4% of the anti-CCP negative RA-patients were anti-CarP positive. The frequencies of anti-CCP antibodies was in the pre-sympomatic individuals 35.7% (95%CI 31.3-40.4) and 74.6% (95%CI 67.9-80.3) in the RA patients

Conclusions These results indicate that the anti-CarP antibodies could be involved in the pathogenesis of RA independent of anti-CCP antibodies

References

  1. Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GMC, van Veelen PA, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc. Natl. Acad. Sci. U. S. A. 2011;108(42):17372-7.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.4530

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.